2025
1. Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant. Thomas S, Roche E, Desai P, et al. Sci Rep. 2025;15(1):3028. doi:10.1038/s41598-024-77186-z
2. Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors. Pacaud R, Thomas S, Chaudhuri S, Lazar A, Timmerman LA, Munster PN. Breast Cancer Res. 2025;27(1):8. doi:10.1186/s13058-024-01954-y
2024
3. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies. Tsang ES, Aggarwal RR, Bergsland EK, et al. JCO Precis Oncol. 2024;8:e2400328. doi:10.1200/PO.24.00328
4. ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors. Chen CT, Khanna V, Kummar S, et al. Cancer Res Commun. Published online August 23, 2024. doi:10.1158/2767-9764.CRC-24-0115
5. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Maldonado E, Rathmell WK, Shapiro GI, et al. Cancer Res Commun. 2024;4(7):1793-1801. doi:10.1158/2767-9764.CRC-24-0213
6. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. Tsang ES, Dhawan MS, Pacaud R, et al. JCO Precis Oncol. 2024;8:e2300494. doi:10.1200/PO.23.00494
7. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Munster P, Iannotti N, Cho DC, et al. Cancer Res Commun. 2024;4(3):785. doi:10.1158/2767-9764.CRC-24-0133
8. Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. Carneiro BA, Cavalcante L, Mahalingam D, et al. Clin Cancer Res. 2024;30(3):522-531. doi:10.1158/1078-0432.CCR-23-1916
2023
9. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Munster P, Iannotti N, Cho DC, et al. Cancer Res Commun. 2023;3(12):2572-2584. doi:10.1158/2767-9764.CRC-22-0461
10. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Razak ARA, Wang HM, Chang JY, et al. Target Oncol. 2023;18(6):853-868. doi:10.1007/s11523-023-00997-z
11. Vaccinia (Smallpox) for the Treatment of Ovarian Cancer-Turning an Old Foe Into a Friend? Tsang ES, Munster PN. JAMA Oncol. 2023;9(7):894-896. doi:10.1001/jamaoncol.2023.0983
12. ATM-SPARK: A GFP phase separation-based activity reporter of ATM. Li X, Chung CI, Yang J, Chaudhuri S, Munster PN, Shu X. Sci Adv. 2023;9(9):eade3760. doi:10.1126/sciadv.ade3760
2022
13. Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead. Tsang ES, Munster PN. OTT. 2022;Volume 15:1509-1518. doi:10.2147/OTT.S322297
14. Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Munster PN, Greenstein AE, Fleming GF, et al. Clinical Cancer Research. 2022;28(15):3214-3224. doi:10.1158/1078-0432.CCR-21-4363
15. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Tsang ES, Aggarwal RR, Dhawan MS, et al. Cancer Research Communications. 2022;2(7):570-576. doi:10.1158/2767-9764.CRC-22-0028
2021
16. Immunotherapy in breast cancer: A clinician’s perspective. Chaudhuri S, Thomas S, Munster P. Journal of the National Cancer Center. 2021;1(2):47-57. doi:10.1016/j.jncc.2021.01.001
2020
17. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Terranova-Barberio M, Pawlowska N, Dhawan M, et al. Nat Commun. 2020;11(1):3584. doi:10.1038/s41467-020-17414-y
2019
18. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Munster P, Mita M, Mahipal A, et al. CMAR. 2019;Volume 11:10463-10476. doi:10.2147/CMAR.S208720
19. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. Wieduwilt MJ, Pawlowska N, Thomas S, et al. Clinical Cancer Research. 2019;25(16):4917-4923. doi:10.1158/1078-0432.CCR-19-0171
20. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. Konstantinopoulos PA, Waggoner S, Vidal GA, et al. JAMA Oncol. 2019;5(8):1141. doi:10.1001/jamaoncol.2019.1048
21. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. Guglin M, Krischer J, Tamura R, et al. Journal of the American College of Cardiology. 2019;73(22):2859-2868. doi:10.1016/j.jacc.2019.03.495
2018
22. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Munster P, Krop IE, LoRusso P, et al. Br J Cancer. 2018;119(9):1086-1093. doi:10.1038/s41416-018-0235-2
23. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ferrarotto R, Eckhardt G, Patnaik A, et al. Annals of Oncology. 2018;29(7):1561-1568. doi:10.1093/annonc/mdy171
24. Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer. Park J, Thomas S, Zhong AY, et al. Sci Rep. 2018;8(1):92. doi:10.1038/s41598-017-18436-1
2017
25. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Terranova-Barberio M, Thomas S, Ali N, et al. Oncotarget. 2017;8(69):114156-114172. doi:10.18632/oncotarget.23169
26. Host histone acetylation unlocks HDAC inhibitor potential. Terranova-Barberio M, Thomas S, Munster PN. Oncotarget. 2017;8(63):106161-106162. doi:10.18632/oncotarget.22422
27. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Bartelink IH, Prideaux B, Krings G, et al. Breast Cancer Res. 2017;19(1):107. doi:10.1186/s13058-017-0896-4
28. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Dhawan MS, Bartelink IH, Aggarwal RR, et al. Clinical Cancer Research. 2017;23(21):6400-6410. doi:10.1158/1078-0432.CCR-17-0703
29. Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer. Thomas S, Chen S, Sbitany H, et al. Plastic & Reconstructive Surgery. 2017;140(3):537-544. doi:10.1097/PRS.0000000000003579
30. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. Aggarwal R, Thomas S, Pawlowska N, et al. JCO. 2017;35(11):1231-1239. doi:10.1200/JCO.2016.70.5350
2016
31. Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome. Munster PN. JAMA Oncol. 2016;2(8):1089. doi:10.1001/jamaoncol.2016.0614
32. Epigenetic Modifiers in Immunotherapy: a Focus on Checkpoint Inhibitors. Terranova-Barberio M, Thomas S, Munster PN. Immunotherapy. 2016;8(6):705-719. doi:10.2217/imt-2016-0014
33. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Thomas S, Aggarwal R, Jahan T, et al. Annals of Oncology. 2016;27(5):947-952. doi:10.1093/annonc/mdw044
34. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Munster P, Aggarwal R, Hong D, et al. Clinical Cancer Research. 2016;22(8):1932-1939. doi:10.1158/1078-0432.CCR-15-1665
35. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Chien AJ, Cockerill A, Fancourt C, et al. Breast Cancer Res Treat. 2016;155(3):521-530. doi:10.1007/s10549-016-3701-7
2015
36. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Raha P, Thomas S, Thurn KT, Park J, Munster PN. Breast Cancer Res. 2015;17(1):26. doi:10.1186/s13058-015-0533-z
37. A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma. Bendell JC, Kelley RK, Shih KC, et al. Cancer. 2015;121(19):3481-3490. doi:10.1002/cncr.29422
38. More Options for Fertility Preservation for Patients With Cancer. Munster PN. JCO. 2015;33(22):2413-2415. doi:10.1200/JCO.2015.61.9304
39. Ovarian Protection during Adjuvant Chemotherapy. Oktay K, Rodriguez-Wallberg K, Munster P. N Engl J Med. 2015;372(23):2268-2270. doi:10.1056/NEJMc1504241
40. Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with Immunotherapy. Park J, Thomas S, Munster PN. Epigenomics. 2015;7(4):641-652. doi:10.2217/epi.15.16
41. Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors. Daud AI, Ashworth MT, Strosberg J, et al. JCO. 2015;33(9):1060-1066. doi:10.1200/JCO.2014.57.5027
2014
42. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K–mTOR pathway inhibition in patients with solid tumor malignancies. Aggarwal R, Grabowsky J, Strait N, Cockerill A, Munster P. Cancer Chemother Pharmacol. 2014;74(2):359-365. doi:10.1007/s00280-014-2510-0
43. New protein kinase inhibitors in breast cancer: afatinib and neratinib. Zhang X, Munster PN. Expert Opinion on Pharmacotherapy. 2014;15(9):1277-1288. doi:10.1517/14656566.2014.913570
2013
44. Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling. Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN. Molecular Cancer Therapeutics. 2013;12(10):2078-2087. doi:10.1158/1535-7163.MCT-12-1242
45. Fertility preservation and breast cancer: A complex problem. Munster PN. Oncology (Williston Park). 2013;27(6):533-539.
46. Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. Thomas S, Thurn KT, Raha P, Chen S, Munster PN. PLoS One. 2013;8(7):e68973. doi:10.1371/journal.pone.0068973
2012
47. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. Munster PN, Moore AP, Ismail-Khan R, et al. J Clin Oncol. 2012;30(5):533-538. doi:10.1200/JCO.2011.34.6890
2011
48. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN. Breast Cancer Res Treat. 2011;130(2):437-447. doi:10.1007/s10549-011-1364-y
49. Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Munster PN, Daud AI. Expert Opin Investig Drugs. 2011;20(11):1565-1574. doi:10.1517/13543784.2011.617740
50. Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Raha P, Thomas S, Munster PN. Epigenomics. 2011;3(4):451-470. doi:10.2217/epi.11.72
51. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Munster PN, Thurn KT, Thomas S, et al. Br J Cancer. 2011;104(12):1828-1835. doi:10.1038/bjc.2011.156
52. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Thurn KT, Thomas S, Moore A, Munster PN. Future Oncol. 2011;7(2):263-283. doi:10.2217/fon.11.2
2009
53. A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer. Munster PN, Rubin EH, Van Belle S, et al. Clinical Cancer Research. 2009;15(22):7077-7084. doi:10.1158/1078-0432.CCR-09-1214
54. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Munster PN, Marchion D, Thomas S, et al. Br J Cancer. 2009;101(7):1044-1050. doi:10.1038/sj.bjc.6605293
55. Estradiol in breast cancer treatment: reviving the past. Munster PN, Carpenter JT. JAMA. 2009;302(7):797-798. doi:10.1001/jama.2009.1223
56. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Thomas S, Munster PN. Cancer Lett. 2009;280(2):184-191. doi:10.1016/j.canlet.2008.12.026
57. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Munster P, Marchion D, Bicaku E, et al. Clin Cancer Res. 2009;15(7):2488-2496. doi:10.1158/1078-0432.CCR-08-1930
58. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Daud AI, Dawson J, DeConti RC, et al. Clin Cancer Res. 2009;15(7):2479-2487. doi:10.1158/1078-0432.CCR-08-1931
59. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN. Mol Cancer Ther. 2009;8(4):794-801. doi:10.1158/1535-7163.MCT-08-0985
2008
60. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Biçaku E, Marchion DC, Schmitt ML, Münster PN. Cancer Res. 2008;68(5):1513-1519. doi:10.1158/0008-5472.CAN-07-2822
2007
61. Development of histone deacetylase inhibitors for cancer treatment. Marchion D, Münster P. Expert Rev Anticancer Ther. 2007;7(4):583-598. doi:10.1586/14737140.7.4.583
2005
62. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Clin Cancer Res. 2005;11(23):8467-8475. doi:10.1158/1078-0432.CCR-05-1073
63. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Mol Cancer Ther. 2005;4(12):1993-2000. doi:10.1158/1535-7163.MCT-05-0194
64. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Cancer Res. 2005;65(9):3815-3822. doi:10.1158/0008-5472.CAN-04-2478
2004
65. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. J Cell Biochem. 2004;92(2):223-237. doi:10.1002/jcb.20045
